Heart drug developer Kardigan Inc. priced its IPO shares at $16 — bringing in $400 million — ahead of open-market sales of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results